American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Upstream Bio, Inc. (UPB)

$2.74 -8.36% NASDAQ: UPB · 15-min delayed

WALTHAM, Massachusetts
Public · NASDAQ: UPB
75 employees

Visit website Follow

$348.8MMarket cap

$2.9MRevenue · FY2025

-$143.4MNet income

75Employees

UPBNASDAQ

2024IPO

About Upstream Bio, Inc.

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: UPB
Employees: 75
IPO date: Oct 11, 2024
Headquarters: 890 WINTER STREET, SUITE 200
WALTHAM, Massachusetts 02451
Phone: 781-208-2466
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: UPB Nasdaq
SEC CIK: 2022626
LEI: 549300I1AHR8KMMFIS52
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Upstream Bio, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/upstream-bio-inc/"><img src="https://americancompanies.com/badge/upstream-bio-inc.svg" alt="Upstream Bio, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Upstream Bio, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $2.9M
Net income: -$143.4M
Total assets: $353.8M
Market cap: $348.8M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: UPB

$2.74 -8.36%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$2.74 $32.60

52-week range

Market cap: $348.8M
Shares outstanding: 127.3M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Oct 11, 2024

Upstream Bio, Inc. (UPB) Stock Price

Reported a net loss of $143.4M in FY2025.
Trading 92% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Upstream Bio, Inc..

Write a review

Newsroom

News about Upstream Bio, Inc.

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 GlobeNewswire Inc. · 2026-09-08 · positive Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsight GlobeNewswire Inc. · 2026-04-23 · positive Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight GlobeNewswire Inc. · 2026-04-07 · positive From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker Benzinga · 2026-04-07 · neutral Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting GlobeNewswire Inc. · 2026-03-01 · positive Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 GlobeNewswire Inc. · 2026-02-26 · positive

News & sentiment via Polygon.io

FAQ

Upstream Bio, Inc.: frequently asked questions

Is Upstream Bio, Inc. an American company?

Upstream Bio, Inc. is a US-based company headquartered in Waltham, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Upstream Bio, Inc. headquartered?

Upstream Bio, Inc. is headquartered in Waltham, Massachusetts, United States.

Is Upstream Bio, Inc. publicly traded?

Yes — Upstream Bio, Inc. is a publicly traded company. Its stock trades under the ticker symbol UPB on the NASDAQ.

What does Upstream Bio, Inc. do?

Upstream Bio, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore